Key result
A newly developed monoclonal antibody (#106) demonstrated high binding reactivity to FMDV type A and detected specific antibodies in vaccinated cattle sera more effectively than a commercial assay.
Why the study?
Foot-and-mouth disease virus type A is a common cause of outbreaks, making serological diagnosis important to confirm infection and evaluate vaccine efficacy.
A newly developed monoclonal antibody (#106) demonstrates high specificity and sensitivity for detecting antibodies against Foot-and-Mouth Disease Virus Type A, offering a potentially improved diagnostic tool.
Answers are grounded in this paper and cite their sources.
May aid FMDV type A serodiagnosis in livestock; leaves open field validation before diagnostic or vaccine use.
Foot-and-mouth disease (FMD) is a highly contagious and economically devastating disease affecting cloven-hoofed livestock worldwide. FMD virus (FMDV) type A is one of the most common causes of FMD outbreaks among the seven FMDV serotypes, and its serological diagnosis is therefore important to confirm FMDV type A infection and to determine FMD vaccine efficacy. Here, we generated monoclonal antibodies (mAbs) specific to FMDV type A via hybridoma systems using an inactivated FMDV type A (A22/Iraq/1964) and found 4 monoclones (#29, #106, #108, and #109) with high binding reactivity to FMDV type A among 594 primary clones. In particular, the #106 mAb had a higher binding reactivity to the inactivated FMDV type A than the other mAbs and a commercial mAb. Moreover, the #106 mAb showed no cross-reactivity to inactivated FMDV type South African territories 1, 2, and 3, and low reactivity to inactivated FMDV type O (O1 Manisa). Importantly, the solid-phase competitive ELISA (SPCE) using horseradish peroxidase (HRP)-conjugated #106 mAb detected FMDV type A-specific Abs in sera from FMD type A-vaccinated cattle more effectively than a commercial SPCE. These results suggest that the newly developed FMDV type A-specific mAb might be useful for diagnostic approaches for detecting Abs against FMDV type A.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2019) studied Foot-and-mouth disease (FMD). #106 monoclonal antibody (mAb) vs. Commercial mAb / commercial SPCE was evaluated on Detection of FMDV type A-specific antibodies in sera. A newly developed monoclonal antibody (#106) demonstrated high binding reactivity to FMDV type A and detected specific antibodies in vaccinated cattle sera more effectively than a commercial assay.
Synapse has enriched 10 related papers. Consider them for comparative context: